Objective: Personal protective equipment (PPE) use is frequently construed as inconvenient and disturbing by health care professionals (HCPs). We hypothesized that new-onset symptoms among HCPs may be associated with extended use of PPE and aimed to investigate risk factors related with new-onset symptoms. In addition, the effects of new-onset symptoms on working performance were evaluated.Methods: In this cross-sectional study, 315 participants filled out a questionnaire that contains 4 main parts: (1) demographics, (2) new-onset symptoms with PPE use, (3) PPE usage hours, and (4) personal opinion about the effect of sensed symptoms on working performance.Results: The mean age was 31.58 ± 4.6 years, and 50.5% (n = 159) were female. New-onset symptom rate was 66% (n = 208). The most common new-onset symptom was headache (n = 115, 36.5%) followed by breathing difficulty-palpitation (n = 79, 25.1%), and dermatitis (n = 64, 20.3%). Extended use of PPE, smoking, and overweight were independently associated with developing new-onset symptoms. A clear majority of symptomatic participants pointed out the impact on working performance (193/208, 92.7%).Conclusion: Hospitals should take the necessary precautions (eg, shorter shifts and more frequent breaks) to prevent symptoms associated with PPE and ensure that HCPs comply with these precautions.
The COVID-19 related high morbidity and mortality have led to a common fear and anxiety. This study aimed to determine the state/trait and death anxiety levels of patients with myocardial infarction (MI) and COVID-19 pneumonia. The study was conducted at the emergency department of a tertiary hospital in Central Anatolia of Turkey. 120 patients with myocardial infarction , 120 patients with COVID-19 pneumonia, and 120 healthy volunteers as a control group were included in the study. The participants filled out the questionnaire that included the State-Trait Anxiety Inventory (STAI) and the Thorson–Powell’s Revised Death Anxiety Scale (RDAS). All scores of patient groups were significantly higher than the control group. There was no significant difference in terms of STAI-S, STAI-T, and RDAS scores between COVID-19 pneumonia and MI groups. The anxiety risk increased 2.14-fold for STAI-T and 1.97-fold for STAI-S in patients with COVID-19 pneumonia compared to the control group. In this study, the state/trait and death anxiety levels of patients with COVID-19 pneumonia were as high as patients with myocardial infarction.COVID-19 pneumonia-related anxiety was associated with chronic diseases and smoking. Knowing the level of anxiety in these patients is important to provide better health services in the emergency departments.